News Related to Anktiva

Related coverage linked through entity extraction aliases.

ImmunityBio Receives EU Authorization for ANKTIVA Bladder Cancer Treatment

Feb 14, 2026

The European Commission granted conditional marketing authorization for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, marking the first approved immunotherapy for this indication in Europe.

ImmunityBio's Anktiva Advances Toward EU Approval for Bladder Cancer

Feb 14, 2026

The European Medicines Agency recommended conditional marketing authorization for Anktiva in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer in December 2025.